목적:UFT와 경구용 leucovorin (LV) 요법은 진행성 대장암 환자의 치료에서 5-Flurouracil/LV 급속 정주법과 같은 효과를 보이면서 더 안전하고 편리하다. 저자들은 진행성 대장암 환자에서 oxaliplatin과 UFT/LV 요법의 효과와 안전성을 조사하였다. 방법:1999년 1월부터 2001년까지 전이성 또는 재발성 대장암으로 진단받았던 28명의 환자를 대상으로 하였다. 치료 방법은 제 1일에 oxaliplatin 130 mg/m2을 2시간에 걸쳐 정주하였고, 제 1일에서 21일까지 UFT 300 mg/m2과 LV 30 mg을 경구투여하였다. 치료는 질병이 진행할 때까지 3주 간격으로 시행하였다. 결과:28명의 환자 중 1명이 완전 관해, 10명이 부분 관해로 전체 관해율은 39.3%였다. 무진행 생존기간과 전체 생존기간의 중앙값은 각각 6.0개월과 18.2개월이었다. 말초신경병증이 가장 흔한 부작용이었으나 모두에서 1, 2도로 경미하였고 가역적이었다. 전체 129주기 중 3도 이상의 부작용은 3%에서만 관찰되었는데, 호중구 감소가 1.5%, 혈소판 감소가 1.5%이었다. 치료 관련 사망은 없었다. 결론:Oxaliplatin과 UFT, 경구 LV 요법은 진행성 대장암 환자에서 효과적인 치료법이고, 부작용은 수용할 만 하였다. 향후 전향적인 3상 연구가 이루어져야겠다.

Background:UFT/oral leucovorin (LV) provided a safer, more convenient oral alternative to bolus i.v. 5-Fluorouracil/LV regimen for advanced colorectal cancer while producing equivalent survival. We evaluated the efficacy and safety of a combination of oxaliplatin and UFT/LV in patients with advanced colorectal cancer. Methods:From January 1999 to December 2001, a total 28 patient with metastatic or relapsed colorectal cancer were enrolled in this study. Treatment was consisted of oxaliplatin 130 mg/m2 i.v. for 2 hours on day 1, and UFT 300 mg/m2 p.o. and LV 30 mg p.o. on day 1-21. Chemotherapy repeated every three weeks until disease progression. Results:Of the 28 patients, 1 complete response and 10 partial responses were observed. The overall response rate was 39.3%. The estimated median time to progression and survival were 6.0 months and 18.2 months, respectively. Peripheral neuropathy was the most common adverse effect. But, peripheral neuropathy was mild (grade 1, 2) and reversible. From the 129 cycles analyzed, grade 3, 4 adverse effects were observed only 3% included neutropenia (1.5%), and thrombocytopenia (1.5%). There were no treatment-related deaths. Conclusion:This combination of oxaliplatin and UFT/oral leucovorin is active and feasible in patients with advanced colorectal cancer. The regimen deserve further evaluation in a phase III prospective study.

Background:UFT/oral leucovorin (LV) provided a safer, more convenient oral alternative to bolus i.v. 5-Fluorouracil/LV regimen for advanced colorectal cancer while producing equivalent survival. We evaluated the efficacy and safety of a combination of oxaliplatin and UFT/LV in patients with advanced colorectal cancer. Methods:From January 1999 to December 2001, a total 28 patient with metastatic or relapsed colorectal cancer were enrolled in this study. Treatment was consisted of oxaliplatin 130 mg/m2 i.v. for 2 hours on day 1, and UFT 300 mg/m2 p.o. and LV 30 mg p.o. on day 1-21. Chemotherapy repeated every three weeks until disease progression. Results:Of the 28 patients, 1 complete response and 10 partial responses were observed. The overall response rate was 39.3%. The estimated median time to progression and survival were 6.0 months and 18.2 months, respectively. Peripheral neuropathy was the most common adverse effect. But, peripheral neuropathy was mild (grade 1, 2) and reversible. From the 129 cycles analyzed, grade 3, 4 adverse effects were observed only 3% included neutropenia (1.5%), and thrombocytopenia (1.5%). There were no treatment-related deaths. Conclusion:This combination of oxaliplatin and UFT/oral leucovorin is active and feasible in patients with advanced colorectal cancer. The regimen deserve further evaluation in a phase III prospective study.

Colorectal neoplasm, Oxaliplatin, Tegafur, Uracil